Product image of Imipenem/Cilastatin Atb (Cilastatin, Imipenem) supplied by GNH India

Imipenem/Cilastatin Atb

Active Ingredient:
Cilastatin, Imipenem
Origin:
EU

Imipenem/Cilastatin Atb (Cilastatin, Imipenem)

Imipenem, the active ingredient in Imipenem/Cilastatin Atb, is a carbapenem antibiotic presented as an intravenous formulation for injection use. It treats severe bacterial infections, including intra‑abdominal, urinary, skin, and central nervous system infections, in hospitalized adult patients.

GNH India supplies Imipenem/Cilastatin Atb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Antibiotice Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections in the hospital setting.
  • Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens to achieve clinical cure.
  • Complicated urinary tract infections: eradicates resistant Gram‑negative organisms to resolve infection.
  • Skin and soft tissue infections: targets resistant Staphylococcus and Gram‑negative bacteria for effective healing.
  • Febrile neutropenia: offers rapid bacterial clearance in immunocompromised patients.
  • Bacterial meningitis: penetrates the cerebrospinal fluid to treat susceptible meningitic pathogens.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting the final stages of bacterial cell‑wall peptidoglycan synthesis, leading to cell lysis. Cilastatin, co‑administered, blocks renal dehydropeptidase I, preventing enzymatic degradation of imipenem and thereby extending its antibacterial activity in the body.

Side Effects

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: may be watery and self‑limiting.
  • Rash: erythematous skin eruptions.
  • Elevated liver enzymes: transient transaminase rise.
  • Headache: mild discomfort.
  • Injection site pain: local irritation.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment.
  • Anaphylaxis: severe allergic reaction requiring immediate care.
  • Clostridioides difficile‑associated diarrhea: possible colitis.
  • Thrombocytopenia: reduced platelet count.
  • Renal dysfunction: worsening kidney function.
  • Pseudomembranous colitis: rare but serious intestinal inflammation.

Precautions & Warnings

Before initiating therapy, consider patient‑specific factors and monitor for adverse events.

  • Renal function assessment: adjust dosing in patients with impaired clearance.
  • History of seizures: evaluate risk before use.
  • Allergy history: avoid in patients with known carbapenem hypersensitivity.
  • Concomitant valproic acid: monitor for reduced antiepileptic levels.
  • Pregnancy and lactation: weigh benefits against potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Imipenem/cilastatin may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

  • Valproic acid: reduces plasma concentrations, risking seizure breakthrough.
  • CNS stimulants (e.g., quinidine, phenobarbital): increase seizure propensity.
  • Renal dehydropeptidase inhibitors: may alter cilastatin activity.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: monitor renal function and electrolytes.
  • Aminoglycosides: increased risk of nephrotoxicity.
  • Warfarin: observe INR for possible anticoagulation changes.

Frequently Asked Questions

Imipenem/Cilastatin Atb is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft tissue infections, febrile neutropenia, and bacterial meningitis. It is administered in hospital settings where broad‑spectrum coverage is required.

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing cross‑linking of peptidoglycan strands and causing cell lysis. Cilastatin protects imipenem from renal dehydropeptidase I, extending its antibacterial activity.

The specific dose and infusion rate are determined by the prescribing clinician based on infection severity, renal function, and patient characteristics. Dosage regimens are individualized and should follow local prescribing guidelines.

Safety data are limited; the drug should be used in pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case carefully.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Imipenem/cilastatin offers a broad spectrum that includes many resistant Gram‑negative and anaerobic organisms, similar to meropenem but with a slightly different stability profile. Cilastatin uniquely protects the drug from renal degradation, allowing higher systemic exposure.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and not frozen. Once reconstituted, it must be used within the time frame specified in the product labeling and stored under the same temperature conditions.

Imipenem/Cilastatin is given intravenously, typically as a bolus or short infusion. The exact administration method, rate, and duration are determined by the prescriber and should follow aseptic technique and institutional protocols.

Serious risks include seizures, especially in patients with renal impairment, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and medical intervention are essential if these events occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or other carbapenems should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid without close monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin, Imipenem

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT